India's Food Watchdog Takes On Nestle Over Baby Formula Claims

Well, this certainly got some attention. India's food safety watchdog, the Food Safety and Standards Authority of India (FSSAI), has just thrown down the gauntlet, initiating legal action against none other than Nestle India. The target? Certain infant nutrition products, leading to a noticeable tremor in Nestle India's share price – a drop of nearly 3% on September 18, 2026, before a slight recovery to close almost flat.

So, what's the big fuss about? It seems the FSSAI has some serious concerns, particularly around promotional claims made on two popular infant formula products: NAN Excella Pro Stage 1 and Lactogen Pro 1. You see, on NAN Excella Pro Stage 1, claims like "5 HMOs" (human milk oligosaccharides) and "whey protein" caught their eye. For Lactogen Pro 1, it was the assertion that its "whey protein" is "easy to digest." Now, these might sound innocuous, but for the FSSAI, they're red flags, allegedly contravening specific rules set out in the 2020 Food Safety and Standards (Foods for Infant Nutrition) Regulations. These regulations, along with the much older Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act of 1992 – often simply called the IMS Act – are pretty strict, aiming to prevent any marketing tactics that could unduly sway parents towards infant formula over breastfeeding.

But wait, there's more to these charges than just marketing. The FSSAI also flagged an issue with a follow-up formula from Nestle India. After testing, both initially and then through a referral lab, a sample of this product was found to have a biotin content that simply didn't meet the prescribed standards. In essence, it was deemed 'substandard' under the very same 2020 infant nutrition regulations.

Naturally, Nestle India isn't taking these allegations lying down. A spokesperson for the company firmly stated that their products are "fully compliant with all the applicable regulations." They even went a step further, emphasizing that the labels in question had been "approved by the expert committee of FSSAI" itself. From their perspective, any statements on their labels are purely "factual in nature" and "supported by scientific literature" – quite the confident defense, wouldn't you say?

This isn't the first time Nestle's infant nutrition practices have come under international scrutiny, and it’s a crucial bit of background. Just in 2024, a report by the Swiss NGO Public Eye made waves, highlighting what seemed to be a concerning discrepancy: some Nestlé infant formula products sold in lower-income countries, India included, apparently contained more sugar than identical products marketed in European nations. While not directly related to these specific FSSAI cases, it certainly adds to the ongoing global conversation about ethical marketing and product consistency for such vulnerable consumers.

For advocates like Dr. Arun Gupta, chief coordinator of the Breastfeeding, this move by the FSSAI is a welcome development. It signals that regulators are indeed keeping a vigilant eye on the sensitive market of infant nutrition. Ultimately, these legal proceedings, unfolding in New Delhi, underscore the immense responsibility food manufacturers carry when it comes to the health and well-being of our youngest and most vulnerable.